Uhlenbruch Mark, Polke Markus, von Eiff Damian, Koryllos Aris, Krüger Stefan
Klinik für Pneumologie, Kardiologie, internistische Intensivmedizin, Florence-Nightingale-Krankenhaus, Düsseldorf, Germany.
Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.
Pneumologie. 2025 Jan 22. doi: 10.1055/a-2512-8349.
Patients with interstitial lung disease (ILD) and especially with idiopathic pulmonary fibrosis(IPF) suffer from reduced survival expectation and risk of exacerbations. Lung cancer is a relevant comorbidity in ILD patients and associated with impaired survival.The most frequent ILD among patients with NSCLC (Non-small cell lung cancer) is idiopathic pulmonary fibrosis (IPF), which is associated with an greater decline in lung function and a higher risk of death.The prevalence of lung cancer in patients with ILD is up to 10% and in autopsy studies a prevalence up to 48% has been found.There are no guidelines for patients with lung cancer and ILD. Moreover, no adequate evidence is available.Therefore, we reviewed currently available literature to present an overview of the state of the art.In this review we focus on staging and treatment of the comorbidity of lung cancer and ILD.
间质性肺疾病（ILD）患者，尤其是特发性肺纤维化（IPF）患者，预期生存期缩短且有病情加重的风险。肺癌是ILD患者的一种相关合并症，与生存期受损有关。非小细胞肺癌（NSCLC）患者中最常见的ILD是特发性肺纤维化（IPF），其与肺功能下降幅度更大及死亡风险更高相关。ILD患者中肺癌的患病率高达10%，在尸检研究中发现患病率高达48%。目前尚无针对肺癌合并ILD患者的指南。此外，也没有充分的证据。因此，我们回顾了当前可得的文献，以呈现最新的研究概况。在本综述中，我们重点关注肺癌与ILD合并症的分期及治疗。
